AbCellera Biologics Inc. (NASDAQ: ABCL) has started dosing participants in a Phase 1 clinical trial of ABCL635 for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE